biote Corp
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
BTMD$1.08-2.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
| Total | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accumulated · Stockholders’ | |||||||||||||||||||||
| Additional · Other · Deficit · Non- · Total | |||||||||||||||||||||
| Class A Common Stock · Class V Voting Stock · Paid-in · Accumulated · Comprehensive · Treasury · Attributable to · controlling · Stockholders’ | |||||||||||||||||||||
| Shares · Amount · Shares · Amount · Capital · Deficit · Loss · Stock · biote Corp. · Interest · Deficit | |||||||||||||||||||||
| Balance at December 31, 2023 | 34,254,883 | $3 | 28,819,066 | $3 | $— | $(29,391) | $(12) | $— | $(29,397) | $(7,149) | $(36,546) | ||||||||||
| Distributions | — | — | — | — | — | — | — | — | — | (2,112) | (2,112) | ||||||||||
| Net loss | — | — | — | — | — | (2,070) | — | — | (2,070) | (3,740) | (5,810) | ||||||||||
| Other comprehensive income (loss) | — | — | — | — | — | — | (2) | — | (2) | (3) | (5) | ||||||||||
| Share-based compensation | — | — | — | — | — | 1,763 | — | — | 1,763 | — | 1,763 | ||||||||||
| Vesting of RSUs | 177,843 | — | — | — | — | (155) | — | — | (155) | 155 | — | ||||||||||
| Exercise of stock options | 80,598 | — | — | — | — | (1,831) | — | — | (1,831) | 2,155 | 324 | ||||||||||
| Common stock repurchased | (740,921) | — | — | — | — | — | — | (4,088) | (4,088) | — | (4,088) | ||||||||||
| Shares issued in connection with acquisition | 291,829 | — | — | — | — | 381 | — | — | 381 | 1,193 | 1,574 | ||||||||||
| Balance at March 31, 2024 | 34,064,232 | $3 | 28,819,066 | $3 | $— | $(31,303) | $(14) | $(4,088) | $(35,399) | $(9,501) | $(44,900) | ||||||||||
| Distributions | — | — | — | — | — | — | — | — | — | (2,091) | (2,091) | ||||||||||
| Net loss | — | — | — | — | — | (6,322) | — | — | (6,322) | (4,153) | (10,475) | ||||||||||
| Other comprehensive income (loss) | — | — | — | — | — | — | (3) | — | (3) | — | (3) | ||||||||||
| Share-based compensation | — | — | — | — | — | 2,841 | — | — | 2,841 | — | 2,841 | ||||||||||
| Vesting of RSUs | 215,190 | — | — | — | — | (19,536) | (7) | — | (19,543) | 19,543 | — | ||||||||||
| Issuance of stock under purchase plans | 35,698 | — | — | — | — | (812) | — | — | (812) | 958 | 146 | ||||||||||
| Exercise of stock options | 63,503 | — | — | — | — | (2,827) | (1) | — | (2,828) | 3,066 | 238 | ||||||||||
| Common stock repurchased | (256,043) | — | — | — | — | — | — | (1,511) | (1,511) | — | (1,511) | ||||||||||
| Shares issued in connection with acquisition | — | — | — | — | 267 | — | — | 267 | — | 267 | |||||||||||
| Exchanges of Class V voting stock | 1,946,408 | — | (1,946,408) | — | — | 4,022 | 2 | — | 4,024 | (4,024) | — | ||||||||||
| Legal Settlement - Repurchase of Shares | (5,075,090) | — | (21,651,005) | (2) | — | (126,306) | 1 | (1) | (126,308) | (2,108) | (128,416) | ||||||||||
| Legal Settlement - Liabilities | — | — | — | — | — | 41,424 | — | — | 41,424 | — | 41,424 | ||||||||||
| TRA liability | — | — | — | — | — | 829 | — | — | 829 | — | 829 | ||||||||||
| Balance at June 30, 2024 | 30,993,898 | $3 | 5,221,653 | $1 | $— | $(137,723) | $(22) | $(5,600) | $(143,341) | $1,690 | $(141,651) | ||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
| Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Accumulated · Stockholders’ | ||||||||||
| Additional · Other · Deficit · Non- · Total | ||||||||||
| Class A Common Stock · Class V Voting Stock · Paid-in · Accumulated · Comprehensive · Attributable to · controlling · Stockholders’ | ||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Loss | biote Corp. | Interest | Deficit | |
| Balance at December 31, 2022 | 9,655,387 | $1 | 48,565,824 | $5 | $— | $(44,460) | $(5) | $(44,459) | $(13,815) | $(58,274) |
| Distributions | — | — | — | — | — | — | — | — | (3,093) | (3,093) |
| Net loss | — | — | — | — | — | (6,805) | — | (6,805) | (14,625) | (21,430) |
| Other comprehensive income | — | — | — | — | — | — | — | — | 1 | 1 |
| Share-based compensation | — | — | — | — | — | 2,170 | — | 2,170 | — | 2,170 |
| Vesting of RSUs | 426,208 | — | — | — | — | 1,915 | (4) | 1,911 | (1,911) | — |
| Exercise of stock options | 105,049 | — | — | — | — | 2,043 | (3) | 2,040 | (1,620) | 420 |
| Litigation settlement | 375,000 | — | — | — | — | 1,199 | — | 1,199 | — | 1,199 |
| Exchanges of Class V voting stock | 7,953,258 | 1 | (7,953,258) | (1) | — | 208 | — | 208 | (208) | — |
| TRA liability | — | — | — | — | — | (4,802) | — | (4,802) | — | (4,802) |
| Balance at March 31, 2023 | 18,514,902 | $2 | 40,612,566 | $4 | $— | $(48,532) | $(12) | $(48,538) | $(35,271) | $(83,809) |
| Distributions | — | — | — | — | — | — | — | — | (3,495) | (3,495) |
| Net loss | — | — | — | — | — | (5,143) | — | (5,143) | (7,952) | (13,095) |
| Other comprehensive loss | — | — | — | — | — | — | — | — | (1) | (1) |
| Share-based compensation | — | — | — | — | — | 2,647 | — | 2,647 | — | 2,647 |
| Vesting of RSUs | 326,261 | — | — | — | — | (3,932) | (1) | (3,933) | 3,933 | — |
| Settlement of warrants | 3,088,473 | — | — | — | — | 15,986 | (1) | 15,985 | 1,530 | 17,515 |
| Exchanges of Class V voting stock | 5,793,500 | 1 | (5,793,500) | (1) | — | (14,419) | (4) | (14,423) | 14,423 | — |
| TRA liability | — | — | — | — | — | 7,000 | — | 7,000 | — | 7,000 |
| Balance at June 30, 2023 | 27,723,136 | $3 | 34,819,066 | $3 | $— | $(46,393) | $(18) | $(46,405) | $(26,833) | $(73,238) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.